<DOC>
	<DOCNO>NCT02748304</DOCNO>
	<brief_summary>The purpose study observe effect sorafenib combine aspirin prevent recurrence high-risk patient hepatocellular carcinoma .</brief_summary>
	<brief_title>Sorafenib Combined With Aspirin Prevent Recurrence High-risk Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>The recurrence hepatocellular carcinoma ( HCC）is main problem treatment . Although method interferon may effective prevent recurrence , still clear effective approach widely accept everyone . Sorafenib , kind tyrosine kinase inhibitor , inhibit proliferation induce apoptosis tumor cell inhibit raf/MEK/ERK pathway , anti-angiogenesis target Vascular Endothelial Growth Factor Receptor ( VEGFR ) , become standard treatment advance HCC patient . Although STORM study show adjuvant sorafenib patient significantly affect recurrence-free survival , time recurrence , overall survival . The patient recruit study mostly early stage , middle late stage patient , whether sorafenib reduce tumor recurrence surgical resection prolong survival remain study . Aspirin kind nonsteroidal anti-inflammatory drug . It first hint aspirin 's potential role tumor prevention treatment Gasic find tumor metastasis reduce thrombocytopenia mouse , research confirm aspirin treatment significantly reduce tumor metastasis . In recent year , lot epidemiological evidence clinical trial find aspirin play important role cancer prevention , time , experimental study find also play role tumor treatment . Our previous animal experiment find combination sorafenib aspirin reverse negative effect sorafenib promote tumor metastasis , obviously prolong survival tumor-burdened nude mouse . So , study observe effect sorafenib combine aspirin prevent recurrence high-risk patient hepatocellular carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>The characteristic treatment history : 1 . No sorafenib treatment history , sorafenib allergy . 2 . No chemotherapy , radiotherapy transcatheter arterial chemoembolization ( TACE ) treatment history surgery . The characteristic tumor : 1 . The pathological result hepatocellular carcinoma . 2 . Meet following article : Pathological prompt microvascular invasion ( MVI ) class II , incorporate following : Tumor number &gt; 3 , Tumor size &gt; 8cm , Tumor margin clear complete capsule . With embolus Portal vein , hepatic vein bile duct . Preoperative rupture invasion adjacent organ . The positive cut edge . Residual lesion show Postoperative digital subtraction angiography ( DSA ) . Alpha fetoprotein ( AFP ) drop normal range two month surgery . The characteristic patient : 1 . The patient age 1875 . 2 . The American Society Anesthesiologists ( ASA）score IIII . 3 . No history esophageal varix gastrointestinal bleeding . 4 . The Childpugh score A . 5 . Routine blood test : leukocyte &gt; 2.5*10^9 , platelet &gt; 60*10^9 . 6 . The Prothrombin time prolong less 2 second . 7 . The Eastern Cooperative Oncology Group ( ECOG ) score less 2 point Sorafenib treatment surgery . Pregnant lactating woman . The Childpugh score BC . Patients malignant tumor . Patients mental illness . Patients participate clinical trial last three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>